These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1948542)

  • 21. The treatment of acquired factor VIII inhibitors: worldwide experience with porcine factor VIII concentrate. International Acquired Hemophilia Study Group.
    Kessler CM; Ludlam CA
    Semin Hematol; 1993 Apr; 30(2 Suppl 1):22-7. PubMed ID: 8480193
    [No Abstract]   [Full Text] [Related]  

  • 22. [Factor VIII inhibitors--their characteristics and clinical significance].
    Dmoszyńska A; Kniaź M; Sokołowska B
    Pol Arch Med Wewn; 1987 Dec; 78(6):333-40. PubMed ID: 3152083
    [No Abstract]   [Full Text] [Related]  

  • 23. Factor VIII Inhibitors. Natural autoantibodies and anti-idiotypes.
    Gilles JG; Vanzieleghem B; Saint-Remy JM
    Semin Thromb Hemost; 2000; 26(2):151-5. PubMed ID: 10919407
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Inhibitors against factor VIII in hemophilia. A review of treatment possibilities and personal results].
    Scheibel E; Feddersen C
    Ugeskr Laeger; 1985 Nov; 147(47):3803-7. PubMed ID: 3934824
    [No Abstract]   [Full Text] [Related]  

  • 25. IgG subclass changes in response to replacement therapy with clotting factor VIII.
    Shakib F
    Monogr Allergy; 1986; 19():262-5. PubMed ID: 3093849
    [No Abstract]   [Full Text] [Related]  

  • 26. Long-term persistence of anti-factor VIII antibody-secreting cells in hemophilic mice after treatment with human factor VIII.
    Hausl C; Maier E; Schwarz HP; Ahmad RU; Turecek PL; Dorner F; Reipert BM
    Thromb Haemost; 2002 May; 87(5):840-5. PubMed ID: 12038787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hemophilia factor VIII therapy. Immunological tolerance. A clinical perspective.
    White GC; Greenwood R; Escobar M; Frelinger JA
    Haematologica; 2000 Oct; 85(10 Suppl):113-6. PubMed ID: 11187862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of severe bleeding in hemophilia A with factor VIII inhibitor.
    Mahasandana C; Suvatte V; Tanphaichitr VS; Bejrachandra S; Chandanayingyong D
    J Med Assoc Thai; 1988 Mar; 71(3):154-8. PubMed ID: 3133440
    [No Abstract]   [Full Text] [Related]  

  • 29. Inhibitors of factor VIII: detection and treatment.
    Brettler DB
    Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():21-5. PubMed ID: 7886576
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Summary report of the First International Conference on inhibitors in haemophilia A.
    Lacroix-Desmazes S; Scott DW; Goudemand J; Van Den Berg M; Makris M; Van Velzen AS; Santagostino E; Lillicrap D; Rosendaal FR; Hilger A; Sauna ZE; Oldenburg J; Mantovani L; Mancuso ME; Kessler C; Hay CRM; Knoebl P; Di Minno G; Hoots K; Bok A; Brooker M; Buoso E; Mannucci PM; Peyvandi F
    Blood Transfus; 2017 Oct; 15(6):568-576. PubMed ID: 27893354
    [No Abstract]   [Full Text] [Related]  

  • 31. Is a change of factor VIII product a risk factor for the development of a factor VIII inhibitor?
    Baglin T; Beacham E
    Thromb Haemost; 1998 Dec; 80(6):1036-7. PubMed ID: 9869186
    [No Abstract]   [Full Text] [Related]  

  • 32. [Improvement in anti-hemophilic preparations and its problems. 3. Treatment of hemophilia patients with inhibitors; induction of immune tolerance by a low or intermediate dose regimen].
    Iizuka A
    Rinsho Ketsueki; 1988 May; 29(5):640-8. PubMed ID: 3145995
    [No Abstract]   [Full Text] [Related]  

  • 33. The treatment of factor VIII inhibitors--a general overview.
    White GC; Roberts HR
    Vox Sang; 1996; 70 Suppl 1():19-23. PubMed ID: 8869464
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction of immune tolerance in a 7-year-old hemophiliac with an anaphylactoid inhibitor.
    Harper JL; Gill JC; Hopp RJ; Evans J; Haire WD
    Thromb Haemost; 1995 Oct; 74(4):1039-41. PubMed ID: 8560409
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative immunogenicity of recombinant B domain-deleted porcine factor VIII and Hyate:C in hemophilia A mice presensitized to human factor VIII.
    Parker ET; Craddock HN; Barrow RT; Lollar P
    J Thromb Haemost; 2004 Apr; 2(4):605-11. PubMed ID: 15102015
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The evidence behind inhibitor treatment with porcine factor VIII.
    Lee CA
    Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():5-8. PubMed ID: 12214138
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Porcine factor VIII therapy in patients with factor VIII inhibitors.
    Hay C; Lozier JN
    Adv Exp Med Biol; 1995; 386():143-51. PubMed ID: 8851022
    [No Abstract]   [Full Text] [Related]  

  • 38. [Combined plasmapheresis and immunosuppression in hemophilia in a patient with antibodies].
    Révész T; Mátyus J; Goldschmidt B; Harsányi V
    Orv Hetil; 1980 Jul; 121(29):1753-4. PubMed ID: 6779250
    [No Abstract]   [Full Text] [Related]  

  • 39. Induction of immune tolerance by neonatal intravenous injection of human factor VIII in murine hemophilia A.
    Madoiwa S; Yamauchi T; Hakamata Y; Kobayashi E; Arai M; Sugo T; Mimuro J; Sakata Y
    J Thromb Haemost; 2004 May; 2(5):754-62. PubMed ID: 15099282
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibitors in young boys with haemophilia.
    Lusher JM
    Baillieres Best Pract Res Clin Haematol; 2000 Sep; 13(3):457-68. PubMed ID: 11030045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.